These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17540437)

  • 1. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease.
    Bellone S; Frera G; Landolfi G; Romani C; Bandiera E; Tognon G; Roman JJ; Burnett AF; Pecorelli S; Santin AD
    Gynecol Oncol; 2007 Sep; 106(3):513-20. PubMed ID: 17540437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
    Kurai J; Chikumi H; Hashimoto K; Yamaguchi K; Yamasaki A; Sako T; Touge H; Makino H; Takata M; Miyata M; Nakamoto M; Burioka N; Shimizu E
    Clin Cancer Res; 2007 Mar; 13(5):1552-61. PubMed ID: 17332301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
    Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
    Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.
    Amaro A; Mirisola V; Angelini G; Musso A; Tosetti F; Esposito AI; Perri P; Lanza F; Nasciuti F; Mosci C; Puzone R; Salvi S; Truini M; Poggi A; Pfeffer U
    Eur J Cancer; 2013 Oct; 49(15):3353-65. PubMed ID: 23849826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
    Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
    Pander J; Heusinkveld M; van der Straaten T; Jordanova ES; Baak-Pablo R; Gelderblom H; Morreau H; van der Burg SH; Guchelaar HJ; van Hall T
    Clin Cancer Res; 2011 Sep; 17(17):5668-73. PubMed ID: 21788356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy.
    Bellone S; Palmieri M; Gokden M; Joshua J; Roman JJ; Pecorelli S; Cannon MJ; Santin AD
    Gynecol Oncol; 2003 Oct; 91(1):231-40. PubMed ID: 14529687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma.
    Kawaguchi Y; Kono K; Mimura K; Sugai H; Akaike H; Fujii H
    Int J Cancer; 2007 Feb; 120(4):781-7. PubMed ID: 17096332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab promotes immunotoxicity against rhabdomyosarcoma in vitro.
    Herrmann D; Seitz G; Warmann SW; Bonin M; Fuchs J; Armeanu-Ebinger S
    J Immunother; 2010 Apr; 33(3):279-86. PubMed ID: 20445348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
    Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
    Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies.
    Derer S; Bauer P; Lohse S; Scheel AH; Berger S; Kellner C; Peipp M; Valerius T
    J Immunol; 2012 Dec; 189(11):5230-9. PubMed ID: 23100515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.
    Levy EM; Sycz G; Arriaga JM; Barrio MM; von Euw EM; Morales SB; González M; Mordoh J; Bianchini M
    Innate Immun; 2009 Apr; 15(2):91-100. PubMed ID: 19318419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
    Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
    Overdijk MB; Verploegen S; van den Brakel JH; Lammerts van Bueren JJ; Vink T; van de Winkel JG; Parren PW; Bleeker WK
    J Immunol; 2011 Sep; 187(6):3383-90. PubMed ID: 21832160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
    Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
    Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
    Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
    J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.